학술논문
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
Document Type
Article
Author
Source
In ESMO Open May 2024 9(5)
Subject
Language
ISSN
2059-7029